<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Filgrastim (including biosimilars): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Filgrastim (including biosimilars): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Filgrastim (including biosimilars): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8446" href="/d/html/8446.html" rel="external">see "Filgrastim (including biosimilars): Drug information"</a> and <a class="drug drug_patient" data-topicid="12472" href="/d/html/12472.html" rel="external">see "Filgrastim (including biosimilars): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F171203"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Granix;</li>
<li>Neupogen;</li>
<li>Nivestym;</li>
<li>Releuko;</li>
<li>Zarxio</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866893"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Grastofil;</li>
<li>Neupogen;</li>
<li>Nivestym</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047358"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Colony-Stimulating Factor</span>;</li>
<li>
<span class="list-set-name">Hematopoietic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462451"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> International considerations: Dosages below expressed as micrograms; 1 mcg = 100,000 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9951685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9951685'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fa37869-72c9-4c1e-a8b6-f2fd082c99b8">Neutropenia with sepsis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia with sepsis: </b>IV, SubQ: 10 mcg/kg/day divided every 12 to 24 hours for 3 to 14 days; most trials have used once daily dosing for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19150703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19150703'])">Ref</a></span>); <b>Note:</b> Trials performed with Neupogen product.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc30d100-3a41-4e1d-9509-e9b35e186da4">Neutropenia, prophylaxis of infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia, prophylaxis of infection:</b> IV, SubQ: 5 to 10 mcg/kg/day for 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19150703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19150703'])">Ref</a></span>); <b>Note:</b> Trials performed with Neupogen product.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="266cacc1-9183-425d-a971-8a77bfd27227">Neutropenia, congenital</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia, congenital:</b> SubQ: Initial: 5 mcg/kg/day, followed by 10 mcg/kg/day; then titrate to response using 10 mcg/kg/day increments every 14 days until target ANC (1,000 to 1,500/mm<sup>3</sup>) is reached and maintained; if ANC exceeds 5,000/mm<sup>3</sup>, dosage should be reduced to lowest effective dose. Typical dose range for response of patients included in the international CN registry is 3 to 10 mcg/kg/day; maximum dose: 120 mcg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18424332','lexi-content-ref-16822461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18424332','lexi-content-ref-16822461'])">Ref</a></span>); <b>Note:</b> Trials performed with Neupogen product.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F171227"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> International considerations: Dosages below expressed as micrograms; 1 mcg = 100,000 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9951685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9951685'])">Ref</a></span>). Dosing may vary by protocol; refer to specific treatment protocol. For larger doses (eg, adolescents), rounding doses to the nearest vial size may enhance patient convenience and reduce costs without compromising clinical response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dbbb9571-dedc-46ff-9b71-f8e42c7daebb">Bone marrow transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone marrow transplantation:</b> Filgrastim and filgrastim biosimilars: Children and Adolescents: IV infusion: 10 mcg/kg/day (administer ≥24 hours after chemotherapy and ≥24 hours after bone marrow infusion); adjust the dose according to the duration and severity of neutropenia; dosage adjustment recommended based on neutrophil response:</p>
<p style="text-indent:-2em;margin-left:4em;">When ANC &gt;1,000/mm<sup>3</sup> for 3 consecutive days: Reduce dose to 5 mcg/kg/day</p>
<p style="text-indent:-2em;margin-left:4em;">If ANC remains &gt;1,000/mm<sup>3</sup> for 3 more consecutive days: Discontinue</p>
<p style="text-indent:-2em;margin-left:4em;">If ANC decreases to &lt;1,000/mm<sup>3</sup>: Resume at 5 mcg/kg/day</p>
<p style="text-indent:-2em;margin-left:4em;">If ANC decreases to &lt;1,000/mm<sup>3</sup> during the 5 mcg/kg/day dose, increase dose to 10 mcg/kg/day and follow the above steps</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46066c01-aba0-4f0c-8481-4c4c2794c3c9">Bone marrow transplantation, slow engraftment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone marrow transplantation, slow engraftment:</b> Filgrastim: Infants, Children, and Adolescents: Limited data available: IV, SubQ: 5 mcg/kg/day administered ≥24 hours after cytotoxic chemotherapy and ≥24 hours after bone marrow infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9877032','lexi-content-ref-11310717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9877032','lexi-content-ref-11310717'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e78eab7-bdcb-4e22-9f99-dc1a85024f65">Chemotherapy-induced neutropenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced neutropenia (myelosuppressive chemotherapy recipients with non-myeloid malignancies):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Filgrastim and filgrastim biosimilars: Infants, Children, and Adolescents: IV, SubQ: 5 mcg/kg/day once daily beginning ≥24 hours after chemotherapy; recommendations for duration of therapy vary: Manufacturer labeling is for up to 14 days or until ANC reaches 10,000/mm<sup>3</sup>; others have suggested a lower target ANC of 5,000/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9877032','lexi-content-ref-11310717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9877032','lexi-content-ref-11310717'])">Ref</a></span>); review treatment-specific protocol for guidance. For subsequent chemotherapy cycles, dose may be increased by 5 mcg/kg based upon patient's previous response to therapy along with duration and severity of neutropenia.</p>
<p style="text-indent:-2em;margin-left:4em;">Tbo-Filgrastim (Granix): Infants, Children, and Adolescents: SubQ: 5 mcg/kg/day once daily; begin ≥24 hours after chemotherapy and continue until anticipated nadir has passed and neutrophil count has recovered to normal range.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec43693e-ae96-4b24-baff-c3c313a39a50">Hematopoietic syndrome of acute radiation syndrome, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic syndrome of acute radiation syndrome, acute: </b>Filgrastim: Infants, Children, and Adolescents: SubQ: 10 mcg/kg/day once daily; begin as soon as possible after suspected or confirmed radiation doses &gt;2 gray (Gy) and continue filgrastim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs or ANC exceeds 10,000/mm<sup>3</sup> after the radiation-induced nadir. ASCO guidelines recommend initiating within 24 hours of exposure of a dose ≥2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for ≥7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26169616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26169616'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90a91b3b-a901-4194-80ff-ceccb9b211d5">Neutropenia, severe, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia, severe, chronic:</b> Filgrastim and filgrastim biosimilars: Infants, Children, and Adolescents: SubQ:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Congenital:</i> Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; median dose: 6 mcg/kg/day</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Idiopathic:</i> Initial: 5 mcg/kg/day in 1 or 2 divided doses; adjust the dose based on ANC and clinical response; median dose: 1.2 mcg/kg/day</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cyclic</i>: Initial: 5 mcg/kg/day in 1 or 2 divided doses; adjust the dose based on ANC and clinical response; median dose: 2.1 mcg/kg/day</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0f38b021-7c4d-4a2e-af28-87b82e2f46bd">Neutropenia in HIV infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia in HIV infection (eg, drug induced):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Trials performed with Neupogen product</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: SubQ: Initial: 1 mcg/kg/day, titrate every 3 days to maintain desired ANC. Doses as high as 20 mcg/kg/day have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1279153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1279153'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: SubQ: Initial: 1 mcg/kg/day, titrate every 3 days to maintain desired ANC. Doses as high as 20 mcg/kg/day have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9456256','lexi-content-ref-1279153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9456256','lexi-content-ref-1279153'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: SubQ: Initial: 300 mcg 1 to 3 times weekly, titrate to desired ANC. Maximum daily dose: 600 mcg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9456256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9456256'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac8f06e3-f126-4bad-ae92-1712eab7de7b">Peripheral blood progenitor cell collection and therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral blood progenitor cell collection and therapy: </b>Filgrastim and filgrastim biosimilars: Infants, Children, and Adolescents: Limited data in infants: SubQ, IV: 10 mcg/kg/day; begin at least 4 days prior to first apheresis and continue until apheresis; discontinue if WBC &gt;100,000/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11223968','lexi-content-ref-11310717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11223968','lexi-content-ref-11310717'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110039"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline impairment at initiation:</p>
<p style="text-indent:-2em;margin-left:4em;">Filgrastim and filgrastim biosimilars: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">Tbo-filgrastim:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Renal toxicity during therapy:</p>
<p style="text-indent:-2em;margin-left:4em;">Filgrastim, filgrastim biosimilars, or tbo-filgrastim: Glomerulonephritis due to filgrastim products: Consider dose reduction or interrupt treatment</p></div>
<div class="block dohp drugH1Div" id="F51110040"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Filgrastim and filgrastim biosimilars: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:2em;">Tbo-filgrastim: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F171207"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8446" href="/d/html/8446.html" rel="external">see "Filgrastim (including biosimilars): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> May round the dose to the nearest vial size for convenience and cost minimization for oncology indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11032599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11032599'])">Ref</a></span>). International considerations: Dosages below expressed as micrograms; 1 mcg = 100,000 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9951685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9951685'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Nivestym (filgrastim-aafi), Releuko (filgrastim-ayow), and Zarxio (filgrastim-sndz) are approved as biosimilars to Neupogen (filgrastim). In Canada, Grastofil is a biosimilar to Neupogen (filgrastim).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2fc5da67-a156-4d3a-b992-03cc9cf621f4">Acute myeloid leukemia following induction or consolidation chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia following induction or consolidation chemotherapy (Neupogen and filgrastim biosimilars):</b>
<b>Note:</b> Do not administer filgrastim in the period 24 hours before to 24 hours after administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ, IV:</b> 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the ANC reaches 10,000/mm<sup>3</sup>. Discontinue if the ANC surpasses 10,000/mm<sup>3</sup> after the expected chemotherapy-induced neutrophil nadir.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62ac398e-8662-4f04-853e-eaeb0e587d10">Alcoholic hepatitis, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcoholic hepatitis, severe (off-label use):</b>
<b>SUBQ</b>
<b>:</b> 5 mcg/kg every 12 hours for 5 consecutive days in combination with standard medical therapy (pentoxifylline and nutritional therapy) and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24935272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24935272'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dbbb9571-dedc-46ff-9b71-f8e42c7daebb">Bone marrow transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone marrow transplantation (Neupogen and filgrastim biosimilars):</b>
<b>IV</b> infusion: 10 mcg/kg/day (administer ≥24 hours after chemotherapy and ≥24 hours after bone marrow infusion); adjust the dose according to the duration and severity of neutropenia; recommended steps based on neutrophil response:</p>
<p style="text-indent:-2em;margin-left:4em;">When ANC &gt;1,000/mm<sup>3</sup> for 3 consecutive days: Reduce dose to 5 mcg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">If ANC remains &gt;1,000/mm<sup>3</sup> for 3 more consecutive days: Discontinue.</p>
<p style="text-indent:-2em;margin-left:4em;">If ANC decreases to &lt;1,000/mm<sup>3</sup>: Resume at 5 mcg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">If ANC decreases to &lt;1,000/mm<sup>3</sup> during the 5 mcg/kg/day dose: Increase dose to 10 mcg/kg/day and follow the above steps.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8fda336a-6d88-4a44-b951-4125fc93a30f">Chemotherapy-induced myelosuppression in nonmyeloid malignancies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced myelosuppression in nonmyeloid malignancies:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Do not administer filgrastim in the period 24 hours before to 24 hours after administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy. WBC growth factors are generally recommended to reduce the risk of neutropenic fever when the anticipated risk of neutropenic fever for a chemotherapy regimen is approximately ≥20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26169616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26169616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Neupogen and filgrastim biosimilars:</b>
<b>SUBQ, IV:</b> 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the absolute neutrophil count (ANC) reaches 10,000/mm<sup>3</sup>. Discontinue when ANC &gt;10,000/mm<sup>3</sup> after the expected chemotherapy-induced neutrophil nadir (to avoid potential excessive leukocytosis).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tbo-filgrastim:</b>
<b>SUBQ:</b> 5 mcg/kg/day; continue until anticipated nadir has passed and neutrophil count has recovered to normal range.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f4c5266-307d-4a2f-b514-846a4b6ed3d6">Fanconi anemia–associated neutropenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fanconi a</b>
<b>nemia–associated neutropenia: Note: </b>Should only be used to manage neutropenia associated with recurrent or serious infections (particularly if the ANC is persistently &lt;500/mm<sup>3</sup>) or for a short time while awaiting hematopoietic cell transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sroka.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sroka.2020'])">Ref</a></span>). Some centers reserve for patients with ANC &lt;200/mm<sup>3</sup> or those with invasive infection (bacterial or fungal) and ANC &lt;1,000/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Olson.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Olson.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>SUBQ:</b> 5 mcg/kg/day; titrate to target ANC 1,500 to 2,000/mm<sup>3</sup> and transition to every-other-day dosing if possible; discontinue if ANC does not improve after 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Olson.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Olson.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59f0abe9-2296-4399-93bb-54a59d001b96">Hematopoietic cell mobilization in healthy donors for peripheral blood stem cells allogeneic transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell mobilization in healthy donors for peripheral blood stem cells allogeneic transplantation (off-label use): SUBQ: </b>10 mcg/kg once daily for 5 days, followed by apheresis on day 5 or on days 5 and 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23075175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23075175'])">Ref</a></span>) <b>or</b> ~10 mcg/kg once daily for 4 consecutive days (for recipients &lt;35 kg) or for 5 consecutive days (for recipients ≥35 kg) followed by apheresis on day 5 or on days 5 and 6; the administered dose was rounded to filgrastim vial sizes of 300 mcg or 480 mcg (total daily dose was ≤~13.3 mcg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109243'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="157baedd-ab2e-4176-9a9c-1348e0e06fec">Hematopoietic cell mobilization prior to betibeglogene autotemcel in beta thalassemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoie</b>
<b>tic cell mobilization prior to betibeglogene autotemcel in beta thalassemia</b>
<b>(off-label use): Note: </b>Decrease filgrastim dose by 50% for WBC &gt;100,000/mm<sup>3</sup> prior to the day of apheresis. Refer to protocol for further mobilization and apheresis details.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with an intact spleen:<b> SUBQ: </b>10 mcg/kg once daily in the morning on mobilization days 1 to 5 (and days 6 and 7 if needed), followed by apheresis, which usually begins on mobilization day 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34891223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34891223'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients without an intact spleen:<b> SUBQ: </b>5 mcg/kg once daily in the morning on mobilization days 1 to 5 (and days 6 and 7 if needed), followed by apheresis, which usually begins on mobilization day 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34891223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34891223'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2c274db-ea5a-48a8-95b4-74a2e455133e">Hematopoietic radiation injury syndrome, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic radiation injury syndrome, acute (Neupogen):</b>
<b>SUBQ</b>
<b>:</b> 10 mcg/kg once daily; begin as soon as possible after suspected or confirmed radiation doses &gt;2 gray (Gy) and continue filgrastim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs or ANC exceeds 10,000/mm<sup>3</sup> after the radiation-induced nadir. The American Society of Clinical Oncology guidelines recommend initiating within 24 hours of exposure of a dose ≥2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for ≥7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26169616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26169616'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60f744a5-f125-4f00-b698-f98973e06ef1">Hepatitis C treatment–associated neutropenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis C treatment–associated neutropenia (off-label use):</b>
<b>SUBQ</b>
<b>:</b> 150 mcg once weekly to 300 mcg 3 times weekly; titrate to maintain ANC between 750 and 10,000/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18194172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18194172'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92ec22ef-a57c-44ab-8694-cfcfe9d47337">Myelodysplastic syndrome–associated anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic syndrome–associated anemia (off-label use):</b>
<b>SUBQ</b>
<b>:</b> 300 mcg weekly in 2 to 3 divided doses (in combination with epoetin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23980065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23980065'])">Ref</a></span>) <b>or</b> 1 mcg/kg once daily (in combination with epoetin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564636'])">Ref</a></span>) <b>or</b> 75 mcg, 150 mcg, or 300 mcg per dose 3 times weekly (in combination with epoetin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12648074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12648074'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2e65224-9194-4558-b0d3-be23027a4f07">Neutropenia in advanced HIV infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia in advanced HIV infection (off-label use):</b>
<b>SUBQ</b>
<b>:</b> Initial: 1 mcg/kg once daily or 300 mcg one to three times per week; titrate to maintain ANC 2,000 to 10,000/mm<sup>3</sup>; doses up to 10 mcg/kg/day or 600 mcg daily were studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9456256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9456256'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac8f06e3-f126-4bad-ae92-1712eab7de7b">Peripheral blood progenitor cell collection and therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral blood progenitor cell collection and therapy (Neupogen and filgrastim biosimilars Nivestym and Zarxio): SUBQ:</b> 10 mcg/kg daily, usually for 6 to 7 days (with apheresis occurring on days 5, 6, and 7). Begin at least 4 days before the first apheresis and continue until the last apheresis; discontinue for WBC &gt;100,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label combination therapy</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with plerixafor (non-Hodgkin lymphoma or multiple myeloma</i>
<i>)</i>: <b>SUBQ:</b> 10 mcg/kg once daily (in combination with plerixafor); begin 4 days before initiation of plerixafor; continue G-CSF on each day prior to apheresis until specified collection goals are met or a maximum total duration of 8 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19720922','lexi-content-ref-19363221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19720922','lexi-content-ref-19363221'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with motixafortide (multiple myeloma):</i> SUBQ: 10 mcg/kg once daily (in combination with motixafortide); begin 4 days before initiation of motixafortide; continue G-CSF on each day prior to apheresis until specified collection goals are met or a maximum total duration of 8 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495201','lexi-content-ref-37069359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495201','lexi-content-ref-37069359'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56405e5a-c041-4bbf-aa15-7e43821d6fc1">Severe chronic neutropenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe chronic neutropenia (Neupogen and filgrastim biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Congenital:</i>
<b>SUBQ:</b> Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; mean dose: 6 mcg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Idiopathic:</i>
<b>SUBQ: </b>Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical response; total daily dose may be administered in 1 or 2 divided doses; mean dose: 1.2 mcg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cyclic:</i>
<b>SUBQ: </b>Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical response; total daily dose may be administered in 1 or 2 divided doses; mean dose: 2.1 mcg/kg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990580"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment at treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Neupogen, filgrastim-biosimilars, and tbo-filgrastim:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large molecular weight): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large molecular weight): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>CRRT: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Nephrotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Glomerulonephritis due to filgrastim:</b> If glomerulonephritis is suspected, evaluate for cause; if likely due to filgrastim, consider dose reduction or treatment interruption.</p></div>
<div class="block doha drugH1Div" id="F50987935"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Neupogen and filgrastim biosimilars: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Tbo-filgrastim: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F58757412"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute respiratory distress syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Life-threatening <b>acute respiratory distress syndrome</b> (ARDS) has been reported. Most cases occur in neutropenic patients, but ARDS has also been reported in non-neutropenic patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11713155','lexi-content-ref-9883815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11713155','lexi-content-ref-9883815'])">Ref</a></span>). Interstitial <b>pneumonia</b> and <b>pleural effusion</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11713155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11713155'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to pharmacologic action; increased neutrophils cause injury to the alveolar capillary wall (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6351681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6351681'])">Ref</a></span>). May also enhance functions of macrophages, monocytes, and endothelial cells via granulocyte colony-stimulating factors (G-CSF) receptors, potentially regulating cytokine production and feedback (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11713155','lexi-content-ref-35115328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11713155','lexi-content-ref-35115328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in neutropenic patients, may occur during neutrophil recovery or 1 to 11 days after neutrophil recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15937498','lexi-content-ref-10354203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15937498','lexi-content-ref-10354203'])">Ref</a></span>). In non-neutropenic patients, reported after 5 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9883815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9883815'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Pneumonia prior to neutropenia recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11940745','lexi-content-ref-35115328','lexi-content-ref-19886984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11940745','lexi-content-ref-35115328','lexi-content-ref-19886984'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rate of leukocyte count elevation after neutropenia recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10354203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10354203'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Aortitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aortitis </b>has been reported in patients receiving granulocyte colony-stimulating factors (G-CSF), including filgrastim (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448091','lexi-content-ref-30016548','lexi-content-ref-33122662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448091','lexi-content-ref-30016548','lexi-content-ref-33122662'])">Ref</a></span>). Manifestations of aortitis may include generalized fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein, WBC count). G-CSF–induced aortitis may occur in the thoracic to abdominal aorta but most commonly presents in the aortic arch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34448091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34448091'])">Ref</a></span>). Resolution of reported cases of aortitis associated with filgrastim have ranged from 1 to 15 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30016548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30016548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; may be caused by pro-inflammatory reaction and neutrophil-mediated damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33122662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33122662'])">Ref</a></span>). G-CSF can cause autoimmune reactions via IL-6 between Th17 cells and CD4+ T cells, leading to aortitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33122662','lexi-content-ref-27094941','lexi-content-ref-28549110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33122662','lexi-content-ref-27094941','lexi-content-ref-28549110'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most reported cases associated with filgrastim occurred 6 to 13 days post administration; however, one case occurred 1 year post administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30016548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30016548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent taxane use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33122662','lexi-content-ref-32128475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33122662','lexi-content-ref-32128475'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• East Asian decent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33122662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33122662'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Capillary leak syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Potentially life-threatening <b>capillary leak syndrome</b> (CLS), characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration, may occur in patients receiving human granulocyte colony-stimulating factors (G-CSF), including filgrastim. CLS episodes may vary in frequency and severity; of the 14 cases of filgrastim-associated CLS, 12 (86%) were categorized as serious and 5 (36%) were fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35570987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35570987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; increase in cytokine production from G-CSF may lead to vascular permeability. Inflammatory process from leukocytosis leading to capillary leak from G-CSF has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35663724','lexi-content-ref-30404164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35663724','lexi-content-ref-30404164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median 8 days after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35570987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35570987'])">Ref</a></span>). <b></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cutaneous vasculitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe cutaneous vasculitis (ie, <b>hypersensitivity angitis</b>) has been reported. Some form of vasculitis occurred in 4.1% of patients with severe chronic neutropenia (SCN) receiving long-term therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12555210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12555210'])">Ref</a></span>). Resolution occurs with discontinuation, and most patients can continue treatment at the same dose or a reduced dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12555210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12555210'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; increased neutrophil count and secondary cytokine release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7529539','lexi-content-ref-11957197','lexi-content-ref-20100783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7529539','lexi-content-ref-11957197','lexi-content-ref-20100783'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; cases have been reported within 3 to 4 days after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24600524','lexi-content-ref-33911730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24600524','lexi-content-ref-33911730'])">Ref</a></span>) and after long-term therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term therapy in patients with SCN <b></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Glomerulonephritis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glomerulonephritis, </b>including rapidly progressive glomerulonephritis has occurred in patients receiving filgrastim. Glomerulonephritis usually resolved after filgrastim dose reduction or discontinuation; however, some cases have persisted and/or resulted in systemic involvement and the development of renal failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7529539','lexi-content-ref-12555210','lexi-content-ref-10931006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7529539','lexi-content-ref-12555210','lexi-content-ref-10931006'])">Ref</a></span>). <b>Henoch-Schönlein purpura</b> associated with glomerulonephritis has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12555210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12555210'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; one hypothesis is that granulocyte colony-stimulating factors (G-CSF) injures endothelial cells, resulting in vasculitis, potentially leading to glomerular basement membrane injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10931006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10931006'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; reported after 1 month to several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7529539','lexi-content-ref-12555210','lexi-content-ref-10931006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7529539','lexi-content-ref-12555210','lexi-content-ref-10931006'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions, including <b>anaphylaxis, angioedema, </b>and <b>urticaria</b> may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8652291','lexi-content-ref-31203715','lexi-content-ref-8809286','lexi-content-ref-25997320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8652291','lexi-content-ref-31203715','lexi-content-ref-8809286','lexi-content-ref-25997320'])">Ref</a></span>). Delayed cutaneous hypersensitivity reactions, ranging from a <b>maculopapular rash</b> to <b>Sweet syndrome</b>, have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15096141','lexi-content-ref-7530069','lexi-content-ref-16487091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15096141','lexi-content-ref-7530069','lexi-content-ref-16487091'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Immediate hypersensitivity reactions: Unknown. In some patients, reactions may be IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8809286']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8809286'])">Ref</a></span>); however, other cases occur with initial exposure, suggesting a non-IgE-mediated mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8652291','lexi-content-ref-25997320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8652291','lexi-content-ref-25997320'])">Ref</a></span>). Polysorbate-80, used as a carrier in filgrastim formulations, may be responsible for some hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33737254','lexi-content-ref-34636131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33737254','lexi-content-ref-34636131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: Rapid; typically occurred within 90 minutes of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31203715','lexi-content-ref-1713300','lexi-content-ref-25997320','lexi-content-ref-23659534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31203715','lexi-content-ref-1713300','lexi-content-ref-25997320','lexi-content-ref-23659534'])">Ref</a></span>); although also reported up to 5 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1713300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1713300'])">Ref</a></span>). Delayed hypersensitivity reactions: Occurred within ~14 days of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15096141','lexi-content-ref-8809286','lexi-content-ref-7530069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15096141','lexi-content-ref-8809286','lexi-content-ref-7530069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between granulocyte colony-stimulating factor (G-CSF) formulations (eg, filgrastim, pegfilgrastim and biosimilars) is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31478530','lexi-content-ref-34636131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31478530','lexi-content-ref-34636131'])">Ref</a></span>). Patients with immediate hypersensitivity reactions to polysorbate 80 may be cross-reactive to polyethylene glycol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33737254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33737254'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myelodysplastic syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been associated with filgrastim when used with chemotherapy and/or radiotherapy in patients with breast or lung cancer, or non-Hodgkin lymphoma (NHL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26450505','lexi-content-ref-30548485','lexi-content-ref-35430673','lexi-content-ref-20385991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26450505','lexi-content-ref-30548485','lexi-content-ref-35430673','lexi-content-ref-20385991'])">Ref</a></span>). Cytogenetic abnormalities and transformation to MDS and AML have also been observed in patients with severe chronic neutropenia (SCN) receiving granulocyte colony-stimulating factors (G-CSF), including filgrastim (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10887102','lexi-content-ref-8541548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10887102','lexi-content-ref-8541548'])">Ref</a></span>). MDS and AML have also occurred in patients with SCN without G-CSF therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; in malignancies, suggested mechanisms include leukemogenesis potentiation in hematopoietic cells that are damaged by chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26450505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26450505'])">Ref</a></span>) and G-CSF allowing more intensive chemotherapy to be given more frequently and with fewer dose reductions increasing total exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30548485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30548485'])">Ref</a></span>). In SCN, G-CSF may rescue malignant cells and/or may cause marrow progenitors to acquire new mutations. G-CSF also prolongs patient survival in SCN, potentially allowing time for the malignant predisposition of SCN to occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11957196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11957196'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in malignancies, onset varied from 1 to 10 years postexposure to G-CSF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26450505','lexi-content-ref-30548485','lexi-content-ref-35430673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26450505','lexi-content-ref-30548485','lexi-content-ref-35430673'])">Ref</a></span>). In SCN, duration of G-CSF to MDS to AML ranged from 1 month to 8.4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10887102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10887102'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use with anthracycline or alkylating agent in breast or lung cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26450505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26450505'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ten or more doses of filgrastim was associated with a higher risk of development of MDS/AML in patients with NHL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30548485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30548485'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35430673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35430673'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Precipitation of sickle cell crisis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Precipitation of<b> sickle cell crisis</b> leading to acute multiorgan failure syndrome has been reported; may be fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9734950','lexi-content-ref-11368061','lexi-content-ref-11405211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9734950','lexi-content-ref-11368061','lexi-content-ref-11405211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to pharmacologic action (ie, increased neutrophil count and activation). Neutrophils likely contribute to microvascular sickle cell trapping leading to vasoocclusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11405211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11405211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; onset of symptoms occurred 3 to 4 days after initiation of granulocyte colony-stimulating factor (G-CSF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9734950','lexi-content-ref-11368061','lexi-content-ref-11405211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9734950','lexi-content-ref-11368061','lexi-content-ref-11405211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increased Hb S levels; G-CSF has been administered safely for mobilization in patients with sickle cell trait with lower Hb S levels (35% to 40%), possibly suggesting a threshold that higher Hb S levels may predispose patients to G-CSF-induced sickle cell crisis. While no major complications were reported, these patients experienced higher symptom scores and required more analgesics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11405211','lexi-content-ref-11806986']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11405211','lexi-content-ref-11806986'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Splenic rupture</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rare cases of <b>splenic rupture</b> have been reported with granulocyte colony-stimulating factor (G-CSF) use for hematology/oncology indications and in healthy donors; may be fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17563733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17563733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to pharmacologic action; G-CSF causes a significant increase of immune myeloid cell density in the spleen through extramedullary hematopoiesis, potentially causing splenic rupture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29330272','lexi-content-ref-16709516','lexi-content-ref-12879437','lexi-content-ref-17563733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29330272','lexi-content-ref-16709516','lexi-content-ref-12879437','lexi-content-ref-17563733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Onset:</i> Varied; reported 2 to 10 days into therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17563733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17563733'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F171171"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported as monotherapy and as part of combination chemotherapy regimens. As reported in adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (43%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (infants, children, adolescents, and adults: 34% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (14%), fatigue (20%), pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (15%), ostealgia (3% to 30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (14%), dyspnea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants, children, adolescents, and adults: 8% to 48%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (≥5%), erythema of skin (≥2%), maculopapular rash (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (infants, children, adolescents, and adults: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≥5%), leukocytosis (≤2%), splenomegaly (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≥5%; including severe hypersensitivity reactions)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (infants, children, adolescents, and adults: 1% to 3%; no evidence of neutralizing response)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (infants, children, adolescents, and adults: 6% to 10%), hypoesthesia (≥5%), insomnia (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (9%), limb pain (infants, children, adolescents, and adults: 6% to 7%), muscle spasm (≥5%), musculoskeletal pain (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≥5%), epistaxis (≥2%), upper respiratory tract infection (≥5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome (Izzedine 2022), vasculitis (aortitis) (Lardieri 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Sweet syndrome (White 2006), urticaria (Nuñez-Acevedo 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal erythropoiesis (extramedullary hematopoiesis), hemophagocytic lymphohistiocytosis (Higuchi 2023), Henoch-Schönlein purpura (Dale 2003), sickle cell crisis (Grigg 2001), splenic rupture (Veerappan 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Doval 2019), angioedema (Martin Munoz 1996), hypersensitivity angiitis (Yoon 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density, myalgia, osteoporosis, rhabdomyolysis (Hacioglu 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis (Dale 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome (Azoulay 2001), hemoptysis, pleural effusion (Azoulay 2001), pneumonia (interstitial) (Azoulay 2001), pulmonary alveolar hemorrhage, pulmonary infiltrates</p></div>
<div class="block coi drugH1Div" id="F171186"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of serious allergic reactions to human granulocyte colony-stimulating factors, such as filgrastim or pegfilgrastim, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Known hypersensitivity to <i>E. coli-</i>derived products.</p></div>
<div class="block war drugH1Div" id="F171168"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse reactions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: White blood cell counts of ≥100,000/mm<sup>3</sup> have been reported with filgrastim doses &gt;5 mcg/kg/day. Doses that increase the ANC beyond 10,000/mm<sup>3</sup> may not result in additional clinical benefit. In patients receiving myelosuppressive chemotherapy, filgrastim discontinuation generally resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, and a return to pretreatment levels in 1 to 7 days. Thrombocytopenia has also been reported with filgrastim products.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Severe chronic neutropenia: Establish diagnosis of severe chronic neutropenia (SCN) prior to initiation; use prior to appropriate diagnosis of SCN may impair or delay proper evaluation and treatment for neutropenia due to conditions other than SCN.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric patients: Colony-stimulating factor (CSF) use in pediatric patients is typically directed by clinical pediatric protocols. The ASCO Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update states that CSFs may be reasonable as primary prophylaxis in pediatric patients when chemotherapy regimens with a high likelihood of febrile neutropenia are employed. Likewise, secondary CSF prophylaxis should be limited to high-risk patients. In pediatric cancers in which dose-intense chemotherapy (with a survival benefit) is used, CSFs should be given to facilitate chemotherapy administration. CSFs should not be used in the pediatric population for non-relapsed acute lymphoblastic or myeloid leukemia when no infection is present (ASCO [Smith 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation therapy recipients: Avoid concurrent radiation therapy with filgrastim products; safety and efficacy have not been established with patients receiving radiation therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The packaging of some dosage forms may contain latex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Other warnings/precautions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• International issues: Some products available internationally may have vial strength and dosing expressed as units (instead of as micrograms). Refer to prescribing information for specific strength and dosing information.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nuclear imaging: Increased bone marrow hematopoietic activity due to colony-stimulating factor use has been associated with transient positive bone-imaging changes; interpret results accordingly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor growth effects: The G-CSF receptor through which filgrastim products act has been found on tumor cell lines. May potentially act as a growth factor for any tumor type (including myeloid malignancies and myelodysplasia). When used for stem cell mobilization, may release tumor cells from marrow, which could be collected in leukapheresis product; potential effect of tumor cell reinfusion is unknown.</p></div>
<div class="block foc drugH1Div" id="F171179"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neupogen: filgrastim 300 mcg/mL (1 mL); filgrastim 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Releuko: Filgrastim-ayow 480 mcg/1.6 mL (300 mcg/mL) (1.6 mL [DSC]) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nivestym: filgrastim-aafi 300 mcg/mL (1 mL); filgrastim-aafi 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Releuko: Filgrastim-ayow 300 mcg/mL (1 mL [DSC]) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Granix: tbo-filgrastim 300 mcg/mL (1 mL); tbo-filgrastim 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neupogen: filgrastim 300 mcg/0.5 mL (0.5 mL); filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nivestym: filgrastim-aafi 300 mcg/0.5 mL (0.5 mL); filgrastim-aafi 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zarxio: filgrastim-sndz 300 mcg/0.5 mL (0.5 mL); filgrastim-sndz 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Granix: tbo-filgrastim 300 mcg/0.5 mL (0.5 mL); tbo-filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Releuko: Filgrastim-ayow 300 mcg/0.5 mL (0.5 mL); Filgrastim-ayow 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F171164"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F171189"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Granix Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg/mL (per mL): $299.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">480 mcg/1.6 mL (per mL): $299.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Neupogen Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg/mL (per mL): $377.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">480 mcg/1.6 mL (per mL): $376.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nivestym Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg/mL (per mL): $262.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">480 mcg/1.6 mL (per mL): $262.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Granix Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg/0.5 mL (per 0.5 mL): $299.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">480 mcg/0.8 mL (per 0.8 mL): $479.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Neupogen Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg/0.5 mL (per 0.5 mL): $400.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">480 mcg/0.8 mL (per 0.8 mL): $637.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Nivestym Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg/0.5 mL (per 0.5 mL): $262.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">480 mcg/0.8 mL (per 0.8 mL): $420.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Zarxio Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg/0.5 mL (per 0.5 mL): $329.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">480 mcg/0.8 mL (per 0.8 mL): $526.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866894"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neupogen: filgrastim 300 mcg/mL (1 mL, 1.6 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nivestym: filgrastim 300 mcg/mL (1 mL); filgrastim 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Grastofil: filgrastim 300 mcg/0.5 mL (0.5 mL); filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neupogen: filgrastim 300 mcg/0.5 mL (0.5 mL); filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nivestym: filgrastim 300 mcg/0.5 mL (0.5 mL); filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52612841"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Allow product to reach room temperature prior to use; after removal from refrigerator wait a minimum of 30 minutes and maximum of 24 hours; discard after out of the refrigerator &gt;24 hours. Nivestym and Zarxio syringes are not recommended for direct administration of doses &lt;0.3 mL; dose cannot be accurately measured.</p>
<p style="text-indent:-2em;margin-left:2em;">SubQ: Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area. Rotate injection site; do not inject into areas that are tender, red, bruised, hardened, or scarred, or sites with stretch marks. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Neupogen (Vial only), Nivestym (Vial only), Zarxio:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chemotherapy-induced neutropenia: </i>Administer IV over 15 to 30 minutes; may also be administered as a continuous infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bone marrow transplantation:</i> Administer as an IV infusion over ≤24 hours. Administer ≥24 hours after chemotherapy and ≥24 hours after bone marrow infusion.</p></div>
<div class="block adm drugH1Div" id="F171183"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV</b> (Neupogen and filgrastim biosimilars): May be administered IV as a short infusion over 15 to 30 minutes (chemotherapy-induced neutropenia) or by continuous infusion (chemotherapy-induced neutropenia) or as an infusion of no longer than 24 hours (bone marrow transplantation).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> May be administered SUBQ (chemotherapy-induced neutropenia, peripheral blood progenitor cell collection, severe chronic neutropenia, hematopoietic radiation injury syndrome). Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area. Rotate injection site; do not inject into areas that are tender, red, bruised, hardened, scaly, or scarred, or sites with stretch marks.</p>
<p style="text-indent:-2em;margin-left:4em;">Some patients (or caregivers) may be appropriate candidates for SUBQ self-administration with proper training; patients/caregivers should follow the manufacturer instructions for preparation and administration. Do not skip doses, change schedule, or discontinue without consulting with health care provider. Some products are available in prefilled syringes either with or without a needle guard; prefilled syringes without a safety needle guard are intended for patient/caregiver self-administration. Prefilled syringes with a safety needle guard are not designed to allow for direct administration of doses &lt;0.3 mL (180 mcg); use vials for doses &lt;0.3 mL (180 mcg). If filgrastim comes in contact with the skin, wash area thoroughly with soap and water; if eye contact occurs, flush exposed eye(s) with water.</p></div>
<div class="block sts drugH1Div" id="F171199"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 2°C to 8°C (36°F to 46°F). Protect from light and direct sunlight. Do not shake. Transport via a pneumatic tube has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional product-specific storage information:</p>
<p style="text-indent:-2em;margin-left:2em;">Neupogen, Nivestym: Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard if frozen more than once. Prior to injection, allow to reach room temperature for a minimum of 30 minutes and up to a maximum of 24 hours. Discard any vial or prefilled syringe left at room temperature for more than 24 hours. Solutions diluted for infusion in D5W may be stored at room temperature for up to 24 hours (infusion must be completed within 24 hours of preparation).</p>
<p style="text-indent:-2em;margin-left:2em;">Neupogen: Store in original carton. Extended storage information may be available for undiluted filgrastim; contact product manufacturer to obtain current recommendations. Sterility has been assessed and maintained for up to 7 days when prepared under strict aseptic conditions (Jacobson 1996; Singh 1994). The manufacturer recommends using within 24 hours due to the potential for bacterial contamination.</p>
<p style="text-indent:-2em;margin-left:2em;">Nivestym: Store in original carton.</p>
<p style="text-indent:-2em;margin-left:2em;">Releuko: Store in original carton. Avoid freezing. Prior to injection, allow to reach room temperature for a minimum of 30 minutes and up to a maximum of 24 hours. Discard any vial or prefilled syringe left at room temperature for more than 24 hours. Solutions diluted for infusion in D5W may be stored at room temperature for up to 4 hours (infusion must be completed within 4 hours of preparation).</p>
<p style="text-indent:-2em;margin-left:2em;">Grastofil [Canadian product]: Accidental one-time exposure to temperatures up to 30ºC (86°F) or exposure to freezing temperatures &lt;0ºC (32°F) does not adversely affect stability. If exposure at &gt;30ºC or &lt;0ºC has been greater than 24 hours or frozen more than once, do not use. May be removed from the refrigerator and stored at room temperature (≤25°C) for a single period of up to 15 days. Do not return to refrigerator.</p>
<p style="text-indent:-2em;margin-left:2em;">Granix: May be removed from 2°C to 8°C (36°F to 46°F) storage for a single period of up to 5 days between 23°C to 27°C (73°F to 81°F). If not used within 5 days, the product may be returned to 2°C to 8°C (36°F to 46°F) up to the expiration date. Dispose of syringes or vials if stored at room temperature for more than 5 days. Exposure to -1°C to -5°C (23°F to 30°F) for up to 72 hours and temperatures as low as -15°C to -25°C (5°F to -13°F) for up to 24 hours do not adversely affect stability.</p>
<p style="text-indent:-2em;margin-left:2em;">Zarxio: Store in original carton. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard if frozen more than once. Prior to injection, allow to reach room temperature for up to a maximum of 4 days. Discard any prefilled syringe left at room temperature for more than 4 days or at &gt;25°C (&gt;77°F) for more than 24 hours. Solutions diluted for infusion in D5W may be stored at room temperature for up to 24 hours (infusion must be completed within 24 hours of preparation).</p></div>
<div class="block usep drugH1Div" id="F53566911"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cancer patients (nonmyeloid malignancies) receiving myelosuppressive chemotherapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Neupogen, Nivestym, Zarxio: Decrease the incidence of infection in patients receiving regimens associated with a high occurrence of severe neutropenia with fever (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Granix (tbo-filgrastim): Reduce the duration of severe neutropenia in patients receiving regimens associated with a clinically significant incidence of febrile neutropenia (FDA approved in ages ≥1 month and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myelogenous leukemia (AML) following induction or consolidation chemotherapy:</b> Reduce time to neutrophil recovery and duration of fever, following induction or consolidation chemotherapy (Neupogen, Nivestym, Zarxio: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cancer patients (nonmyeloid malignancies) receiving bone marrow transplant:</b> Reduce the duration of neutropenia and neutropenia-related events (eg, febrile neutropenia) undergoing myeloablative chemotherapy followed by bone marrow transplantation (Neupogen, Nivestym, Zarxio: FDA approved in ages ≥1 year and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic syndrome of acute radiation syndrome:</b> Improve survival in patients acutely exposed to myelosuppressive doses of radiation (Neupogen: FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral stem cell transplantation:</b> Mobilization autologous hematopoietic progenitor cells into peripheral blood for apheresis collection (Neupogen, Nivestym, Zarxio: FDA approved in ages ≥1 year and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe chronic neutropenia (SCN; chronic administration):</b> Reduce the incidence and duration of neutropenic complications (fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic, or idiopathic neutropenia (Neupogen, Nivestym, Zarxio: FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used for neutropenia in HIV patients receiving zidovudine; neutropenia in advanced HIV infection; neonatal neutropenia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Nivestym (filgrastim-aafi) and Zarxio (filgrastim-sndz) are biosimilar agents; approved uses and ages may vary, see product labeling for additional information.</p></div>
<div class="block mst drugH1Div" id="F171257"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Filgrastim may be confused with efbemalenograstim alfa, eflapegrastim, pegfilgrastim, sargramostim, tbo-filgrastim.</p>
<p style="text-indent:-2em;margin-left:4em;">Neupogen may be confused with Epogen, Neulasta, Nutramigen.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Neupogen [US, Canada, and multiple international markets] may be confused with Neupro brand name for rotigotine [multiple international markets].</p>
<p style="text-indent:-2em;margin-left:4em;">Some products available internationally may have vial strength and dosing expressed as units (instead of as micrograms). Refer to prescribing information for specific strength and dosing information.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299335"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220395"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Belotecan: Granulocyte Colony-Stimulating Factors may enhance the neutropenic effect of Belotecan.  Management: Do not administer granulocyte colony-stimulating factor (G-CSF) until at least 24 hours after completion of belotecan administration. Monitor neutrophil counts and signs/symptoms of neutropenic fever in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Granulocyte Colony-Stimulating Factors may interact via an unknown mechanism with Betibeglogene Autotemcel.  Management: Granulocyte-colony stimulating factor is not recommended for 21 days after betibeglogene autotemcel infusion.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bleomycin: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.  Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of bleomycin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: Filgrastim may enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, the risk of pulmonary toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exagamglogene Autotemcel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Exagamglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tisagenlecleucel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Topotecan. Specifically, the risk for the development of interstitial lung disease may be increased. Granulocyte Colony-Stimulating Factors may enhance the myelosuppressive effect of Topotecan.  Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of topotecan. Additionally, monitor patients closely for the development of interstitial lung disease with this combination.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F171190"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F2734401"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Filgrastim crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Available data do not suggest an association between the use of filgrastim during pregnancy and an increased risk of miscarriage, preterm labor, or adverse fetal outcomes (birth weight or infection) following maternal use for severe chronic neutropenia. Outcome data related to the use of granulocyte-colony stimulating factor (G-CSF) in pregnant patients with congenital, cyclic, or idiopathic neutropenia (Boxer 2015; Zeidler 2014), G-CSF-induced allogeneic peripheral blood stem cells donation (Leitner 2001; Shibata 2003), or chemotherapy-induced neutropenia during pregnancy (Berends 2021; Cardonick 2012) are limited.</p>
<p style="text-indent:0em;margin-top:2em;">Data collected from the Severe Chronic Neutropenia International Registry (SCNIR) note dosing for chronic conditions may need adjusted in pregnant patients; the lowest effective dose to maintain the absolute neutrophil count is recommended (Zeidler 2014).</p>
<p style="text-indent:0em;margin-top:2em;">G-CSF is recommended for pregnant patients who required G-CSF for chronic neutropenia prior to pregnancy and those treated for severe congenital neutropenia; frequent monitoring is recommended, particularly in patients with autoimmune neutropenia. Monitor neutrophil count of the newborn following delivery (Fioredda 2023). Consensus panel guidelines for hematologic malignancies during pregnancy suggest that although data are limited, administration of granulocyte growth factors during pregnancy may be acceptable (Lishner 2016). One review suggests when utilizing for hematopoietic stem cell mobilization (in healthy donors; not a labeled use) avoiding use during the first trimester until additional outcome information is available (Pessach 2013).</p></div>
<div class="block mopp drugH1Div" id="F53566901"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Chemotherapy-induced neutropenia: Complete blood cell count (CBC) with differential and platelets prior to chemotherapy and twice weekly during growth factor treatment</p>
<p style="text-indent:-2em;margin-left:2em;">Bone marrow transplantation: CBC with differential and platelets frequently</p>
<p style="text-indent:-2em;margin-left:2em;">Hematopoietic radiation injury syndrome (acute): CBC at baseline (do not delay filgrastim for baseline CBC) and approximately every 3 days until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs. Estimate absorbed radiation dose (radiation exposure) based on information from public health authorities, biodosimetry (if available), or clinical findings (eg, onset of vomiting or lymphocyte depletion kinetics).</p>
<p style="text-indent:-2em;margin-left:2em;">Peripheral progenitor cell collection: Neutrophil counts after 4 days of filgrastim treatment</p>
<p style="text-indent:-2em;margin-left:2em;">Severe chronic neutropenia: CBC with differential and platelets twice weekly during the first month of therapy and for 2 weeks following dose adjustments; once clinically stable, monthly for 1 year and quarterly thereafter. Monitor bone marrow and karyotype prior to treatment; and monitor marrow and cytogenetics annually throughout treatment</p></div>
<div class="block rerp drugH1Div" id="F53566567"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Blood samples for monitoring the hematologic effects of G-CSF should be drawn just before the next dose </p></div>
<div class="block pha drugH1Div" id="F171167"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Filgrastim is a granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. G-CSFs stimulate the production, maturation, and activation of neutrophils to increase both their migration and cytotoxicity.</p></div>
<div class="block phk drugH1Div" id="F171185"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Filgrastim: Transient increase in neutrophil count is seen 1 to 2 days after filgrastim initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">Tbo-filgrastim: Time to maximum ANC: 3 to 5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Filgrastim: Neutrophil counts generally return to baseline within 4 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Tbo-filgrastim: ANC returned to baseline by 21 days after completion of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 150 mL/kg; Continuous infusion: No evidence of drug accumulation over a 11- to 20-day period.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Systemically degraded</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Filgrastim: SUBQ: 60% to 70%; Tbo-filgrastim: SUBQ: 33%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: 4.4 ± 0.4 hours (Gillan 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Filgrastim: ~3.5 hours; Tbo-filgrastim: 3 to 3.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: SUBQ: Filgrastim: 2 to 8 hours; Tbo-filgrastim: 4 to 6 hours.</p></div>
<div class="block phksp drugH1Div" id="F51192566"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In a study with healthy volunteers, subjects with moderate renal impairment, and subjects with end-stage renal disease (ESRD) (n=4 per group), higher serum concentrations were observed in subjects with ESRD.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F171191"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Neupogen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Neupogen</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lioplim</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Valgrastim</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Filgen | Neupogen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Granulokine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Leucostim</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Neupogen</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Granuven</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Neupogen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tevagrastim</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Scilocyte</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Grastin | Neutrofil</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lioplim</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Neupogen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Neupogen | Neupomax</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Neupogen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Leukoplus</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Neupogen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9734950">
<a name="9734950"></a>Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. <i>Lancet</i>. 1998;351(9107):959. doi:10.1016/S0140-6736(05)60614-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9734950/pubmed" id="9734950" target="_blank">9734950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11368061">
<a name="11368061"></a>Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. <i>Blood</i>. 2001;97(10):3313-3314. doi:10.1182/blood.v97.10.3313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11368061/pubmed" id="11368061" target="_blank">11368061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15096141">
<a name="15096141"></a>Alvarez-Ruiz S, Peñas PF, Fernández-Herrera J, Sánchez-Pérez J, Fraga J, García-Díez A. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. <i>J Eur Acad Dermatol Venereol</i>. 2004;18(3):310-3. doi:10.1111/j.1468-3083.2004.00872.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/15096141/pubmed" id="15096141" target="_blank">15096141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23075175">
<a name="23075175"></a>Anasetti C, Logan BR, Lee SJ, et al; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. <i>N Engl J Med</i>. 2012;367(16):1487-1496. doi:10.1056/NEJMoa1203517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/23075175/pubmed" id="23075175" target="_blank">23075175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23326257">
<a name="23326257"></a>Arora S, Bhargava A, Jasnosz K, Clark B. Relapsing acute kidney injury associated with pegfilgrastim. <i>Case Rep Nephrol Urol</i>. 2012;2(2):165-171. doi:10.1159/000345278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/23326257/pubmed" id="23326257" target="_blank">23326257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11713155">
<a name="11713155"></a>Azoulay E, Attalah H, Harf A, Schlemmer B, Delclaux C. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. <i>Chest</i>. 2001;120(5):1695-1701. doi:10.1378/chest.120.5.1695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11713155/pubmed" id="11713155" target="_blank">11713155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11940745">
<a name="11940745"></a>Azoulay E, Darmon M, Delclaux C, et al. Deterioration of previous acute lung injury during neutropenia recovery. <i>Crit Care Med</i>. 2002;30(4):781-786. doi:10.1097/00003246-200204000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11940745/pubmed" id="11940745" target="_blank">11940745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8652291">
<a name="8652291"></a>Batel-Copel L, Mommeja-Marin H, Oudard S, et al. Anaphylactic reaction after a first filgrastim (granulocyte-colony stimulating factor) injection. <i>Eur J Cancer</i>. 1995;31A(13-14):2428. doi:10.1016/0959-8049(95)00423-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/8652291/pubmed" id="8652291" target="_blank">8652291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29330272">
<a name="29330272"></a>Benguerfi S, Thepault F, Lena H, Ricordel C. Spontaneous splenic rupture as a rare complication of G-CSF injection. <i>BMJ Case Rep</i>. 2018;2018:bcr2017222561. doi:10.1136/bcr-2017-222561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/29330272/pubmed" id="29330272" target="_blank">29330272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11172139">
<a name="11172139"></a>Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. <i>N Engl J Med</i>. 2001;344(3):175-181. doi:10.1056/NEJM200101183440303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11172139/pubmed" id="11172139" target="_blank">11172139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33802196">
<a name="33802196"></a>Berends C, Maggen C, Lok CAR, et al. Maternal and neonatal outcome after the use of G-CSF for cancer treatment during pregnancy. <i>Cancers (Basel)</i>. 2021;13(6):1214. doi:10.3390/cancers13061214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/33802196/pubmed" id="33802196" target="_blank">33802196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7529539">
<a name="7529539"></a>Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. <i>Br J Haematol</i>. 1994;88(4):723-730. doi:10.1111/j.1365-2141.1994.tb05110.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7529539/pubmed" id="7529539" target="_blank">7529539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2471075">
<a name="2471075"></a>Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. <i>N Engl J Med</i>. 1989;320(24):1574-1580. doi:10.1056/NEJM198906153202402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/2471075/pubmed" id="2471075" target="_blank">2471075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25560125">
<a name="25560125"></a>Boxer LA, Bolyard AA, Kelley ML, et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. <i>Obstet Gynecol</i>. 2015;125(1):197-203. doi:10.1097/AOG.0000000000000602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/25560125/pubmed" id="25560125" target="_blank">25560125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18424332">
<a name="18424332"></a>Boztug K, Welte K, Zeidler C, Klein C. Congenital neutropenia syndromes. <i>Immunol Allergy Clin North Am</i>. 2008;28(2):259-275. doi:10.1016/j.iac.2008.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/18424332/pubmed" id="18424332" target="_blank">18424332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33737254">
<a name="33737254"></a>Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden Dangers: Recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. <i>J Allergy Clin Immunol Pract</i>. 2021;9(8):2968-2982. doi:10.1016/j.jaip.2021.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/33737254/pubmed" id="33737254" target="_blank">33737254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17994119">
<a name="17994119"></a>Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. <i>Bone Marrow Transplant</i>. 2008;41(4):331-338. doi:10.1038/sj.bmt.1705908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/17994119/pubmed" id="17994119" target="_blank">17994119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12897302">
<a name="12897302"></a>Calhoun DA, Maheshwari A, Christensen RD. Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed. <i>Pediatrics</i>. 2003;112(2):421-423. doi:10.1542/peds.112.2.421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/12897302/pubmed" id="12897302" target="_blank">12897302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26450505">
<a name="26450505"></a>Calip GS, Malmgren JA, Lee WJ, Schwartz SM, Kaplan HG. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. <i>Breast Cancer Res Treat</i>. 2015;154(1):133-143. doi:10.1007/s10549-015-3590-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/26450505/pubmed" id="26450505" target="_blank">26450505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30548485">
<a name="30548485"></a>Calip GS, Moran KM, Sweiss KI, et al. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. <i>Cancer</i>. 2019;125(7):1143-1154. doi:10.1002/cncr.31914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/30548485/pubmed" id="30548485" target="_blank">30548485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-cardonick.1">
<a name="cardonick.1"></a>Cardonick E, Irfan F, Torres N. The use of Neupogen (filgrastim) or Neulasta (pegfilgrastim) during pregnancy when chemotherapy is indicated for maternal cancer treatment. <i>J Cancer Ther</i>. 2012;3:157-161. doi:10.4236/jct.2012.32021</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19150703">
<a name="19150703"></a>Carr R, Brocklehurst P, Doré CJ, et al. Granulocyte-Macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): A single-blind, multicentre, randomised controlled trial.<i> Lancet</i>. 2009;373(9659):226-33. doi:10.1016/S0140-6736(09)60071-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/19150703/pubmed" id="19150703" target="_blank">19150703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12917944">
<a name="12917944"></a>Carr R, Modi N, Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections. <i>Cochrane Database Syst Rev</i>. 2003;3:CD003066. doi:10.1002/14651858.CD003066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/12917944/pubmed" id="12917944" target="_blank">12917944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11957197">
<a name="11957197"></a>Cottle TE, Fier CJ, Donadieu J, Kinsey SE. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. <i>Semin Hematol</i>. 2002;39(2):134-140. doi:10.1053/shem.2002.31914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11957197/pubmed" id="11957197" target="_blank">11957197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37069359">
<a name="37069359"></a>Crees ZD, Rettig MP, Jayasinghe RG, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. <i>Nat Med</i>. 2023;29(4):869-879. doi:10.1038/s41591-023-02273-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/37069359/pubmed" id="37069359" target="_blank">37069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495201">
<a name="31495201"></a>Crees ZD, Stockerl-Goldstein K, Vainstein A, Chen H, DiPersio JF. GENESIS: phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. <i>Future Oncol</i>. 2019;15(31):3555-3563. doi:10.2217/fon-2019-0380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/31495201/pubmed" id="31495201" target="_blank">31495201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12555210">
<a name="12555210"></a>Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. <i>Am J Hematol</i>. 2003;72(2):82-93. doi:10.1002/ajh.10255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/12555210/pubmed" id="12555210" target="_blank">12555210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35430673">
<a name="35430673"></a>Danese MD, Schenfeld J, Shaw J, et al. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer. <i>Adv Ther</i>. 2022;39(6):2778-2795. doi:10.1007/s12325-022-02141-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/35430673/pubmed" id="35430673" target="_blank">35430673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15365768">
<a name="15365768"></a>Deeren DH, Zachee P, Malbrain ML. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. <i>Ann Hematol</i>. 2005;84(2):89-94. doi:10.1007/s00277-004-0946-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/15365768/pubmed" id="15365768" target="_blank">15365768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11223968">
<a name="11223968"></a>Díaz MA, Kanold J, Vicent MG, Halle P, Madero L, Deméocq F. Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: a state-of-the-art review. <i>Bone Marrow Transplant</i>. 2000;26(12):1291-1298. doi:10.1038/sj.bmt.1702725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11223968/pubmed" id="11223968" target="_blank">11223968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720922">
<a name="19720922"></a>DiPersio JF, Micallef I, Stiff PJ, et al. Phase III prospective randomized double-blinded placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. <i>J Clin Oncol</i>. 2009a;27(28):4767-4773. doi:10.1200/JCO.2008.20.7209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/19720922/pubmed" id="19720922" target="_blank">19720922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19363221">
<a name="19363221"></a>DiPersio JF, Stadtmauer EA, Nadamanee NP, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. <i>Blood</i>. 2009b;113(23):5720-5726. doi:10.1182/blood-2008-08-174946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/19363221/pubmed" id="19363221" target="_blank">19363221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35115328">
<a name="35115328"></a>Doig C, Cooke R, Chua C, Leung T. Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed <i>Pneumocystis jirovecii</i> pneumonia. <i>BMJ Case Rep</i>. 2022;15(2):e242316. doi:10.1136/bcr-2021-242316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/35115328/pubmed" id="35115328" target="_blank">35115328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31203715">
<a name="31203715"></a>Doval D, Choudhary D, Sharma SK, Khandelwal V. Severe hypersensitivity allergic reaction to filgrastim in a healthy stem cell donor. <i>J Oncol Pharm Pract</i>. 2019;25(8):2056-2058. doi:10.1177/1078155219856419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/31203715/pubmed" id="31203715" target="_blank">31203715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37008163">
<a name="37008163"></a>Fioredda F, Skokowa J, Tamary H, et al. The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action. <i>Hemasphere</i>. 2023;7(4):e872. doi:10.1097/HS9.0000000000000872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/37008163/pubmed" id="37008163" target="_blank">37008163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11957196">
<a name="11957196"></a>Freedman MH, Alter BP. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. <i>Semin Hematol</i>. 2002;39(2):128-33. doi:10.1053/shem.2002.31912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11957196/pubmed" id="11957196" target="_blank">11957196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10887102">
<a name="10887102"></a>Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. <i>Blood</i>. 2000;96(2):429-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/10887102/pubmed" id="10887102" target="_blank">10887102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21205990">
<a name="21205990"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):427-431. doi:10.1093/cid/ciq147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/21205990/pubmed" id="21205990" target="_blank">21205990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19330875">
<a name="19330875"></a>Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. <i>Hepatology</i>. 2009;49(4):1335-1374. doi:10.1002/hep.22759<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/19330875/pubmed" id="19330875" target="_blank">19330875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7520770">
<a name="7520770"></a>Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. <i>Blood</i>. 1994;84(5):1427-1433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7520770/pubmed" id="7520770" target="_blank">7520770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7527850">
<a name="7527850"></a>Gilmore MM, Stroncek DF, Korones DN. Treatment of alloimmune neonatal neutropenia with granulocyte colony-stimulating factor. <i>J Pediatr</i>. 1994;125(6 Pt 1):948-951. doi:10.1016/s0022-3476(05)82014-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7527850/pubmed" id="7527850" target="_blank">7527850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31478530">
<a name="31478530"></a>González-Cavero L, Gómez-Traseira C, Fiandor A, Entrala A, Quirce S. Desensitization to filgrastim in a 2-year-old girl with a vaginal endodermal sinus tumor.<i> J Investig Allergol Clin Immunol</i>. 2019;29(4):329-330. doi:10.18176/jiaci.0399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/31478530/pubmed" id="31478530" target="_blank">31478530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35663724">
<a name="35663724"></a>Gotera N, Hasan S, Shrestha P, Heleno C, Tesar A. A case of concurrent leukocytosis and systemic capillary leak syndrome due to pegfilgrastim. <i>Cureus</i>. 2022;14(5):e24640. doi:10.7759/cureus.24640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/35663724/pubmed" id="35663724" target="_blank">35663724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Granix.1">
<a name="Granix.1"></a>Granix (tbo-filgrastim) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grastofil.1">
<a name="Grastofil.1"></a>Grastofil (filgrastim) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19564636">
<a name="19564636"></a>Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). <i>Blood</i>. 2009;114(12):2393-2400. doi:10.1182/blood-2009-03-211797<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/19564636/pubmed" id="19564636" target="_blank">19564636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11405211">
<a name="11405211"></a>Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. <i>Blood</i>. 2001;97(12):3998-9. doi:10.1182/blood.v97.12.3998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11405211/pubmed" id="11405211" target="_blank">11405211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PADE.2008">
<a name="PADE.2008"></a>
<i>Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</i>. Pediatric Adverse Drug Events. February 28, 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20823994">
<a name="20823994"></a>Hacioglu S, Altuntas F, Kaynar L, Sari I, Patiroglu T, Cetin M. Rhabdomyolysis in a healthy peripheral blood stem cell donor following mobilization with filgrastim. <i>Transfus Med Hemother</i>. 2009;36(2):135-137. doi:10.1159/000206822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/20823994/pubmed" id="20823994" target="_blank">20823994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12648074">
<a name="12648074"></a>Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.<i> Br J Haematol</i>. 2003;120(6):1037-1046. doi:10.1046/j.1365-2141.2003.04153.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/12648074/pubmed" id="12648074" target="_blank">12648074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated May 1, 2014. Accessed July 30, 2014. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Updated March 1, 2016. Accessed June 2, 2016. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37769993">
<a name="37769993"></a>Higuchi S, Lee S, Fujita K, Hara T, Tsurumi H. Filgrastim-induced hemophagocytic lymphohistiocytosis in a patient with mantle cell lymphoma: a case report. <i>J Infect Chemother</i>. doi:10.1016/j.jiac.2023.09.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/37769993/pubmed" id="37769993" target="_blank">37769993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9951685">
<a name="9951685"></a>Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) – what is the difference? <i>Med Oncol</i>. 1998;15(4):229-233. doi:10.1007/BF02787205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9951685/pubmed" id="9951685" target="_blank">9951685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1717226">
<a name="1717226"></a>Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. <i>Drugs</i>. 1991;42(2):300-330. doi:10.2165/00003495-199142020-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/1717226/pubmed" id="1717226" target="_blank">1717226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24600524">
<a name="24600524"></a>Ippoliti G, Paulli M, Lucioni M, Lauriola M, D'Armini AM. Leukocytoclastic vasculitis as a complication of recombinant granulocyte colony-stimulating factor therapy in a heart transplant patient. <i>Case Rep Transplant</i>. 2014;2014:160407. doi:10.1155/2014/160407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/24600524/pubmed" id="24600524" target="_blank">24600524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35570987">
<a name="35570987"></a>Izzedine H, Mathian A, Amoura Z, Ng JH, Jhaveri KD. Anticancer drug-induced capillary leak syndrome. <i>Kidney Int Rep</i>. 2022;7(5):945-953. doi:10.1016/j.ekir.2022.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/35570987/pubmed" id="35570987" target="_blank">35570987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8913403">
<a name="8913403"></a>Jacobson PA, West NJ, Spadoni V, Maksym CJ, Pierson C. Sterility of filgrastim (G-CSF) in syringes. <i>Ann Pharmacother</i>. 1996;30(11):1238-1242. doi: 10.1177/106002809603001105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/8913403/pubmed" id="8913403" target="_blank">8913403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15840690">
<a name="15840690"></a>Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. <i>Blood</i>. 2005;106(3):803-811. doi:10.1182/blood-2004-10-3872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/15840690/pubmed" id="15840690" target="_blank">15840690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1713300">
<a name="1713300"></a>Jaiyesimi I, Giralt SS, Wood J. Subcutaneous granulocyte colony-stimulating factor and acute anaphylaxis. <i>N Engl J Med</i>. 1991;325(8):587. doi:10.1056/NEJM199108223250818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/1713300/pubmed" id="1713300" target="_blank">1713300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34636131">
<a name="34636131"></a>Jeter H, Grisanti K, Jantz A, Wadhwa A, Waite E. Filgrastim desensitization in a patient with Hodgkin lymphoma. <i>Pediatr Blood Cancer</i>. 2022;69(1):e29394. doi:10.1002/pbc.29394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/34636131/pubmed" id="34636131" target="_blank">34636131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448091">
<a name="34448091"></a>Jimbo H, Horimoto Y, Okazaki M, Ishizuka Y, Kido H, Saito M. Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report. <i>Surg Case Rep</i>. 2021;7(1):197. doi:10.1186/s40792-021-01282-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/34448091/pubmed" id="34448091" target="_blank">34448091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17914246">
<a name="17914246"></a>Kaida K, Ikegame K, Fujioka T, et al. Kinetics of granulocyte colony-stimulating factor in the human milk of a nursing donor receiving treatment for mobilization of the peripheral blood stem cells. <i>Acta Haematol</i>. 2007;118(3):176-177. doi:10.1159/000109267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/17914246/pubmed" id="17914246" target="_blank">17914246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8541548">
<a name="8541548"></a>Kalra R, Dale D, Freedman M, et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. <i>Blood</i>. 1995;86(12):4579-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/8541548/pubmed" id="8541548" target="_blank">8541548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11806986">
<a name="11806986"></a>Kang EM, Areman EM, David-Ocampo V, et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. <i>Blood</i>. 2002;99(3):850-855. doi:10.1182/blood.v99.3.850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11806986/pubmed" id="11806986" target="_blank">11806986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15937498">
<a name="15937498"></a>Karlin L, Darmon M, Thiéry G, et al. Respiratory status deterioration during G-CSF-induced neutropenia recovery. <i>Bone Marrow Transplant</i>. 2005;36(3):245-250. doi:10.1038/sj.bmt.1705037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/15937498/pubmed" id="15937498" target="_blank">15937498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20100783">
<a name="20100783"></a>Kilic SS, Mustafayeva S, Ipek K, Adim SB. Leukocytoclastic vasculitis in patients with severe congenital neutropenia. <i>J Trop Pediatr</i>. 2010;56(5):359-362. doi:10.1093/tropej/fmp140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/20100783/pubmed" id="20100783" target="_blank">20100783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9251510">
<a name="9251510"></a>Kitamura S, Kinouchi K, Fukumitsu K, Takeuchi M, Matsuyama M, Miyamoto Y. [A risk of pulmonary edema associated with G-CSF pretreatment]. <i>Masui</i>. 1997;46(7):946-950. Japanese.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9251510/pubmed" id="9251510" target="_blank">9251510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9456256">
<a name="9456256"></a>Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection; results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. <i>AIDS</i>. 1998;12(1):65-74. doi:10.1097/00002030-199801000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9456256/pubmed" id="9456256" target="_blank">9456256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8959393">
<a name="8959393"></a>Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. <i>Drug Metab Rev</i>. 1996;28(4):625-658. doi:10.3109/03602539608994020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/8959393/pubmed" id="8959393" target="_blank">8959393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30016548">
<a name="30016548"></a>Lardieri A, McCulley L, Christopher Jones S, Woronow D. Granulocyte colony-stimulating factors and aortitis: A rare adverse event. <i>Am J Hematol</i>. 2018;93(10):E333-E336. doi:10.1002/ajh.25220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/30016548/pubmed" id="30016548" target="_blank">30016548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33122662">
<a name="33122662"></a>Lee SY, Kim EK, Kim JY, et al. The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer. <i>Sci Rep</i>. 2020;10(1):18647. doi:10.1038/s41598-020-75620-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/33122662/pubmed" id="33122662" target="_blank">33122662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11722442">
<a name="11722442"></a>Leitner G, Loidolt H, Greinix HT, et al. Granulocyte colony-stimulating factor-induced allogeneic peripheral stem cell donation during early pregnancy.<i> Br J Haematol</i>. 2001;115(1):233-234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11722442/pubmed" id="11722442" target="_blank">11722442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508. doi:10.1200/JCO.2015.62.4445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9742646">
<a name="9742646"></a>Lisukov IA, Kriuchkova IV, Kulagin AD, et al. Respiratornyĭ distress-sindrom vzroslykh pri vosstanovlenii urovnia neĭtrofilov posle autologichnoĭ transplantatsii kostnogo mozga [The adult respiratory distress syndrome during the recovery of the neutrophil level after autologous bone marrow transplantation].<i> Ter Arkh</i>. 1998;70(7):78-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9742646/pubmed" id="9742646" target="_blank">9742646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34891223">
<a name="34891223"></a>Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for non-β<sup>0</sup>/β<sup>0</sup> genotype β-thalassemia. <i>N Engl J Med</i>. 2022;386(5):415-427. doi:10.1056/NEJMoa2113206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/34891223/pubmed" id="34891223" target="_blank">34891223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20385991">
<a name="20385991"></a>Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. <i>J Clin Oncol</i>. 2010;28(17):2914-2924. doi:10.1200/JCO.2009.25.8723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/20385991/pubmed" id="20385991" target="_blank">20385991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23980065">
<a name="23980065"></a>Malcovati L, Hellström-Lindberg E, Bowen D, et al; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i>. 2013;122(17):2943-2964. doi:10.1182/blood-2013-03-492884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/23980065/pubmed" id="23980065" target="_blank">23980065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16186594">
<a name="16186594"></a>Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. <i>J Clin Oncol</i>. 2005;23(30):7614-7620. doi:10.1200/JCO.2005.02.7243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/16186594/pubmed" id="16186594" target="_blank">16186594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8809286">
<a name="8809286"></a>Martín Muñoz R, Gómez-Bellver MJ, Navarro Pulido AM, Orta Cuevas JC. Probable hypersensitivity reaction to filgrastim. <i>Am J Health Syst Pharm</i>. 1996;53(13):1607. doi:10.1093/ajhp/53.13.1607a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/8809286/pubmed" id="8809286" target="_blank">8809286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12879546">
<a name="12879546"></a>McCullough JM, Sprentall-Nankervis E, Potcova CA, Cease KB. Recovery and biological activity of filgrastim after injection through silicone rubber catheters. <i>Am J Health Syst Pharm</i>. 1995;52(2):186-188. doi:10.1093/ajhp/52.2.186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/12879546/pubmed" id="12879546" target="_blank">12879546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27094941">
<a name="27094941"></a>Miller EB, Grosu R, Landau Z. Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF). <i>Clin Rheumatol</i>. 2016;35(6):1655-1657. doi:10.1007/s10067-016-3253-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/27094941/pubmed" id="27094941" target="_blank">27094941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2789274">
<a name="2789274"></a>Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. <i>J Clin Oncol</i>. 1989;7(10):1554-1562. doi:10.1200/JCO.1989.7.10.1554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/2789274/pubmed" id="2789274" target="_blank">2789274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1279153">
<a name="1279153"></a>Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. <i>J Pediatr</i>. 1992;121(5 Pt 1):797-802. doi:10.1016/s0022-3476(05)81918-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/1279153/pubmed" id="1279153" target="_blank">1279153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neupogen.1">
<a name="Neupogen.1"></a>Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neupogen.1a">
<a name="Neupogen.1a"></a>Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neupogen.2">
<a name="Neupogen.2"></a>Neupogen (filgrastim) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nivestym.1">
<a name="Nivestym.1"></a>Nivestym (filgrastim-aafi) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nivestym.1a">
<a name="Nivestym.1a"></a>Nivestym (filgrastim-aafi) [prescribing information]. Lake Forest, IL: Hospira Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16709516">
<a name="16709516"></a>Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. <i>Haematologica</i>. 2006;91(5 suppl):ECR08.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/16709516/pubmed" id="16709516" target="_blank">16709516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25997320">
<a name="25997320"></a>Nuñez-Acevedo B, Rodríguez-Jiménez B, Domínguez-Ortega J, González-Montellano E, Ibáñez-Heras N, Enrech-Francés S. Desensitization to lenograstim after a life-threatening reaction to filgrastim. <i>J Investig Allergol Clin Immunol</i>. 2015;25(2):158-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/25997320/pubmed" id="25997320" target="_blank">25997320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Olson.2022">
<a name="Olson.2022"></a>Olson TS. Management and prognosis of Fanconi anemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed February 11, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7685433">
<a name="7685433"></a>Okubo Y, Nakazawa K. [Recombinant G-CSF and the interstitial pneumonia during MACOP-B therapy in two cases of non-Hodgkin's lymphoma]. <i>Rinsho Ketsueki</i>. 1993;34(4):473-477. Japanese.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7685433/pubmed" id="7685433" target="_blank">7685433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12879437">
<a name="12879437"></a>O'Malley DP, Whalen M, Banks PM. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. <i>Am J Hematol</i>. 2003;73(4):294-295. doi:10.1002/ajh.10317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/12879437/pubmed" id="12879437" target="_blank">12879437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11032599">
<a name="11032599"></a>Ozer H, Armitage JO, Bennett CL, et al; American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. <i>J Clin Oncol</i>. 2000;18(20):3558-3585. doi:10.1200/JCO.2000.18.20.3558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11032599/pubmed" id="11032599" target="_blank">11032599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23287427">
<a name="23287427"></a>Pessach I, Shimoni A, Nagler A. Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know? <i>Hum Reprod Update</i>. 2013;19(3):259-267. doi:10.1093/humupd/dms053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/23287427/pubmed" id="23287427" target="_blank">23287427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7993409">
<a name="7993409"></a>Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. <i>N Engl J Med</i>. 1994;330(23):1639-1644. doi:10.1056/NEJM199406093302303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7993409/pubmed" id="7993409" target="_blank">7993409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109243">
<a name="23109243"></a>Pulsipher MA, Chitphakdithai P, Logan BR, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i>. 2013;121(1):197-206. doi:10.1182/blood-2012-03-417667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/23109243/pubmed" id="23109243" target="_blank">23109243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Releuko.1">
<a name="Releuko.1"></a>Releuko (filgrastim-ayow) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Releuko.2">
<a name="Releuko.2"></a>Releuko (filgrastim-ayow) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19886984">
<a name="19886984"></a>Rhee CK, Kang JY, et al. Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies. <i>Crit Care</i>. 2009;13(6):R173. doi:10.1186/cc8149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/19886984/pubmed" id="19886984" target="_blank">19886984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16497969">
<a name="16497969"></a>Rosenberg PS, Alter BP, Bolyard AA, et al; Severe chronic neutropenia international registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. <i>Blood</i>. 2006;107(12):4628-4635. doi:10.1182/blood-2005-11-4370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/16497969/pubmed" id="16497969" target="_blank">16497969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9883815">
<a name="9883815"></a>Ruiz-Argüelles GJ, Arizpe-Bravo D, Sánchez-Sosa S, Rojas-Ortega S, Moreno-Ford V, Ruiz-Argüelles A. Fatal G-CSF-induced pulmonary toxicity. <i>Am J Hematol</i>. 1999;60(1):82-83. doi: 10.1002/(sici)1096-8652(199901)60:1&lt;82::aid-ajh18&gt;3.0.co;2-r<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9883815/pubmed" id="9883815" target="_blank">9883815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7530069">
<a name="7530069"></a>Sasaki O, Yokoyama A, Uemura S, et al. Drug eruption caused by recombinant human G-CSF. <i>Intern Med</i>. 1994;33(10):641-643. doi:10.2169/internalmedicine.33.641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7530069/pubmed" id="7530069" target="_blank">7530069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28549110">
<a name="28549110"></a>Sato Y, Kaji S, Ueda H, Tomii K. Thoracic aortitis and aortic dissection following pegfilgrastim administration. <i>Eur J Cardiothorac Surg</i>. 2017;52(5):993-994. doi:10.1093/ejcts/ezx165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/28549110/pubmed" id="28549110" target="_blank">28549110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9877032">
<a name="9877032"></a>Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. <i>Eur J Pediatr</i>. 1998;157(12):955-966. doi:10.1007/s004310050978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9877032/pubmed" id="9877032" target="_blank">9877032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14663166">
<a name="14663166"></a>Shibata H, Yamane T, Aoyama Y, et al. Excretion of granulocyte colony-stimulating factor into human breast milk. <i>Acta Haematol</i>. 2003;110(4):200-201. doi:10.1159/000074226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/14663166/pubmed" id="14663166" target="_blank">14663166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30404164">
<a name="30404164"></a>Shin JI, Lee KH, Lee IR, et al. Systemic capillary leak syndrome (Clarkson syndrome) in cancer patients: A systematic review. <i>J Clin Med</i>. 2018;7(11):418. doi:10.3390/jcm7110418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/30404164/pubmed" id="30404164" target="_blank">30404164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336434">
<a name="29336434"></a>Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: alcoholic liver disease. <i>Am J Gastroenterol.</i> 2018;113(2):175-194. doi: 10.1038/ajg.2017.469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/29336434/pubmed" id="29336434" target="_blank">29336434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7531941">
<a name="7531941"></a>Singh RF, Corelli RL, Guglielmo BJ. Sterility of unit dose syringes of filgrastim and sargramostim. <i>Am J Hosp Pharm</i>. 1994;51(22):2811-2812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/7531941/pubmed" id="7531941" target="_blank">7531941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935272">
<a name="24935272"></a>Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. <i>Am J Gastroenterol.</i> 2014;109(9):1417-1423. doi:10.1038/ajg.2014.154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/24935272/pubmed" id="24935272" target="_blank">24935272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26169616">
<a name="26169616"></a>Smith TJ, Bohlke K, Lyman GH, et al; American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2015;33(28):3199-3212. doi:10.1200/JCO.2015.62.3488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/26169616/pubmed" id="26169616" target="_blank">26169616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16682719">
<a name="16682719"></a>Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. <i>J Clin Oncol</i>. 2006;24(19):3187-3205. doi:10.1200/JCO.2006.06.4451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/16682719/pubmed" id="16682719" target="_blank">16682719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10931006">
<a name="10931006"></a>Sotomatsu M, Kanazawa T, Ogawa C, Watanabe T, Morikawa A. Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (filgrastim). <i>Br J Haematol</i>. 2000;110(1):234-235. doi:10.1046/j.1365-2141.2000.02072-1.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/10931006/pubmed" id="10931006" target="_blank">10931006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sroka.2020">
<a name="Sroka.2020"></a>Sroka I, Frohnmayer L, Van Ravenhorst S, et al, eds. Fanconi anemia clinical care guidelines. 5th edition. Fanconi Anemia Research Fund; 2020. Accessed February 18, 2022. https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32128475">
<a name="32128475"></a>Taimen K, Heino S, Kohonen I, et al. Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. <i>Rheumatol Adv Pract</i>. 2020;4(1):rkaa004. doi:10.1093/rap/rkaa004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/32128475/pubmed" id="32128475" target="_blank">32128475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6351681">
<a name="6351681"></a>Tate RM, Repine JE. Neutrophils and the adult respiratory distress syndrome. <i>Am Rev Respir Dis</i>. 1983;128(3):552-559. doi:10.1164/arrd.1983.128.3.552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/6351681/pubmed" id="6351681" target="_blank">6351681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23659534">
<a name="23659534"></a>Tholpady A, Chiosea I, Lyons JJ, Baird K, Leitman SF. Systemic hypersensitivity reaction mimicking anaphylaxis after first filgrastim administration in a healthy donor. <i>Transfusion</i>. 2013;53(5):1146-1147. doi:10.1111/trf.12149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/23659534/pubmed" id="23659534" target="_blank">23659534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10354203">
<a name="10354203"></a>Todeschini G, Murari C, Bonesi R, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. <i>Eur J Clin Invest</i>. 1999;29(5):453-457. doi:10.1046/j.1365-2362.1999.00474.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/10354203/pubmed" id="10354203" target="_blank">10354203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8656266">
<a name="8656266"></a>Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. <i>J Clin Oncol</i>. 1996;14(6):1957-1960. doi:10.1200/JCO.1996.14.6.1957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/8656266/pubmed" id="8656266" target="_blank">8656266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17563733">
<a name="17563733"></a>Veerappan R, Morrison M, Williams S, Variakojis D. Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. <i>Bone Marrow Transplant</i>. 2007;40(4):361-364. doi:10.1038/sj.bmt.1705736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/17563733/pubmed" id="17563733" target="_blank">17563733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11310717">
<a name="11310717"></a>Wagner LM, Furman WL. Haemopoietic growth factors in paediatric oncology: a review of the literature. <i>Paediatr Drugs</i>. 2001;3(3):195-217. doi:10.2165/00128072-200103030-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/11310717/pubmed" id="11310717" target="_blank">11310717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16822461">
<a name="16822461"></a>Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. <i>Semin Hematol</i>. 2006;43(3):189-195. doi:10.1053/j.seminhematol.2006.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/16822461/pubmed" id="16822461" target="_blank">16822461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16487091">
<a name="16487091"></a>White JM, Mufti GJ, Salisbury JR, du Vivier AW. Cutaneous manifestations of granulocyte colony-stimulating factor. <i>Clin Exp Dermatol</i>. 2006;31(2):206-207. doi:10.1111/j.1365-2230.2005.01996.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/16487091/pubmed" id="16487091" target="_blank">16487091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9190031">
<a name="9190031"></a>Wolach B. Neonatal sepsis: pathogenesis and supportive therapy. <i>Semin Perinatol</i>. 1997;21(1):28-38. doi:10.1016/s0146-0005(97)80017-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/9190031/pubmed" id="9190031" target="_blank">9190031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33911730">
<a name="33911730"></a>Yoon D, Byun HJ, Oh SJ, Park JH, Lee DY. A Case of cutaneous leukocytoclastic vasculitis associated with granulocyte colony-stimulating factor: An unusual presentation. <i>Ann Dermatol</i>. 2020;32(2):164-167. doi:10.5021/ad.2020.32.2.164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/33911730/pubmed" id="33911730" target="_blank">33911730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18194172">
<a name="18194172"></a>Younossi ZM, Nader FH, Bai C, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. <i>J Viral Hepat</i>. 2008;15(5):370-378. doi:10.1111/j.1365-2893.2007.00956.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/18194172/pubmed" id="18194172" target="_blank">18194172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zarxio.1">
<a name="Zarxio.1"></a>Zarxio (filgrastim-sndz) [prescribing information]. Princeton, NJ: Sandoz Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24997149">
<a name="24997149"></a>Zeidler C, Grote UA, Nickel A, et al. Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry.<i> Haematologica</i>. 2014;99(8):1395-1402. doi:10.3324/haematol.2013.099101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/filgrastim-including-biosimilars-pediatric-drug-information/abstract-text/24997149/pubmed" id="24997149" target="_blank">24997149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zynteglo.1">
<a name="Zynteglo.1"></a>Zynteglo (betibeglogene autotemcel) [prescribing information]. Somerville, MA: Bluebird Bio Inc; August 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13301 Version 288.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
